gip/glp-1 receptor agonist drugs Emerging Role of Dual GLP-1 and GIP Agonists | DMSO PDB-101: Molecule of the Month:

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering agents primarily used in managing diabetes and obesity

GLP-1 medications can provide major health benefits, but recent studies have raised questions about a possible link with NAION, a rare optic nerve condition that can cause sudden vision loss

CONTRIBUTED BY REAL CHEMISTRY | BY RITA GLAZE-ROWE ALABAMA A new study on behalf of Real Chemistry has identified which state Medicaid programs cover GLP-1s.The growing popularity of GLP-1 receptor agonists including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound from Eli Lilly has added fuel to an already fiery []

A key feature of the consensus is its endorsement of shared decision-making, taking into account patient goals, preferences, access, and affordability

Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors